Taken together, these data make it clear that GLP-1 receptor agonists are here to stay as consumers continue to seek ways to manage their weight and cardiometabolic health, she says
It is well to be noted that the FDA had in the past identified serious concerns regarding compounded versions of semaglutide as well as tirzepatide, which included the likes of dosing errors, use of unapproved salt forms, and even adverse events, which led to hospitalization in certain cases
Furthermore, the weight loss induced by GLP-1 receptor agonists can decrease obesity-related cancer risks
Things that frequently drive weight gain, and that GLP-1s alone will not fix: Untreated depression or anxiety that drives emotional eating and disrupted sleep Perimenopausal hormone shifts that change body composition and insulin sensitivity ADHD-related dysregulated eating patterns (binge eating, time-blindness around meals, impulsive food decisions) Untreated thyroid dysfunction Insulin resistance, PCOS, or sleep apnea that interact with metabolism Medication side effects from antidepressants, antipsychotics, or other prescriptions This is where being a dual-board-certified Family and Psychiatric-Mental Health Nurse Practitioner changes the conversation
These results were confirmed by fecal ELISA in a validation cohort of patients with AH (Fig
How Do I Choose the Right Semaglutide Attorney
